From the Canadian Press:
A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.
GlaxoSmithKline, in conjunction with Health Canada, is advising patients taking abacavir-containing products - sold under the brand names Ziagen, Kivexa and Trizivir - of concerns raised by a recent study in The Lancet about the possible elevated heart attack risk.
Patients should not stop taking any of the abacavir-containing medications without first consulting their doctor, the company said in a release. Patients should also discuss any serious, pre-existing cardiovascular disease with their physician.
"Health-care professionals thoroughly consider the overall benefit versus the risk of a medication for each individual patient before prescribing," the company said. "If patients have questions regarding their current prescription, they are asked to contact their doctor." ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment